Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)

Black Diamond (BDTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Dec 4, 2025

Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor receptor (EGFR) mutations (NCMs).

Benzinga • Dec 3, 2025

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced topline data from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor receptor (EGFR) mutations (NCMs) and outlined plans for a randomized Phase 2 trial of silevertinib in patients with newly diagnosed glioblastoma (ND GBM).

GlobeNewsWire • Dec 3, 2025

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.

GlobeNewsWire • Dec 2, 2025

Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout

Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline targeting unmet needs. Silevertinib, BDTX's lead candidate, is advancing in NSCLC and glioblastoma, with key clinical updates expected in late 2025 and early 2026. BDTX's financial position is strong, with a cash runway extending into Q4 2027, supported by a recent $70 million payment from Servier.

Seeking Alpha • Nov 20, 2025

Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?

Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Nov 12, 2025

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.

GlobeNewsWire • Nov 6, 2025

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

GlobeNewsWire • Nov 6, 2025

Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?

Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.

Zacks Investment Research • Oct 31, 2025

BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?

ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.

Zacks Investment Research • Oct 22, 2025